Anti-bribery and corruption in the sector

Nigel Layton, our Global Head of Pharma & Life Sciences and UK Head of Investigations, gives his insight on anti-bribery and corruption within the pharma and life sciences sector.

Since 2011 the pharma and life sciences industry has seen 23 prosecutions in the US and the UK and $1.75 billion worth of fines. Speaking to Tarifa Simpson, our Healthcare & Life Sciences Co-Lead, Nigel discusses the tightening regulatory environment, third-party due diligence and the importance of robust, up to date compliance and whistleblowing programs.

Life sciences

Helping life sciences companies have sustainable growth in an innovative manner to deliver better health outcomes for society

Mazars sponsors FT Live Global Pharma Summit

Mazars is committed to supporting the pharma and life sciences sector; helping companies to navigate disruption, embrace innovation and grow with confidence. That’s why we recently partnered with FT Live for their Global Pharma and Biotech Summit - bringing the industry together to explore the latest trends, share top expertise and drive growth.